{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:03:23Z","timestamp":1789639403623,"version":"4.0.0"},"reference-count":37,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infect. Dis. Rep.","Infectious Disease Reports"],"abstract":"<jats:p>Background\/Objectives: Doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) is used as a switch regimen in treatment-experienced people with HIV (PWH), particularly when simplification, lipid improvement, or avoidance of interaction-prone regimens is needed. We evaluated 48-week virologic effectiveness and laboratory changes after switching to DOR\/3TC\/TDF in routine care. Methods: This multicenter retrospective study included adults with HIV who switched to fixed-dose DOR\/3TC\/TDF at seven Italian HIV centers within the Sardinian HIV Network-Sicilian HIV Cohort (SHINe-SHIC) network. The switch visit served as baseline; follow-up data were extracted at 24 and 48 weeks. The primary endpoint was HIV RNA &lt; 50 copies\/mL at 48 weeks in an observed analysis. Secondary endpoints were changes in lipid and lipid-derived parameters, renal function, and hepatic laboratory markers. Results: Ninety-eight participants were included; 75 (76.5%) were male, and the median age was 52.4 years. At 48 weeks, 72\/81 participants (88.9%) had HIV RNA &lt; 50 copies\/mL and 78\/81 (96.3%) had HIV RNA &lt; 200 copies\/mL. Total cholesterol decreased from 199 to 165 mg\/dL (median paired change, \u221222 mg\/dL; p &lt; 0.001), low-density lipoprotein cholesterol from 118 to 106.5 mg\/dL (\u221213.5 mg\/dL; p = 0.001), and triglycerides from 112.5 to 94 mg\/dL (\u221210.5 mg\/dL; p = 0.021). Non-high-density lipoprotein cholesterol and the total cholesterol\/high-density lipoprotein cholesterol ratio improved, whereas high-density lipoprotein cholesterol decreased modestly. Serum creatinine and estimated glomerular filtration rate remained stable. Alanine aminotransferase increased modestly; aspartate aminotransferase and gamma-glutamyl transferase did not significantly change. Conclusions: Switching to DOR\/3TC\/TDF maintained virologic control, improved lipid and lipid-derived parameters, and was not associated with renal function decline among participants with follow-up data. In selected treatment-experienced PWH, DOR\/3TC\/TDF may be useful when lipid improvement, simplification, or management of drug-drug interaction concerns are treatment goals.<\/jats:p>","DOI":"10.3390\/idr18050105","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:03:17Z","timestamp":1789632197000},"page":"105","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Virologic, Lipid, Renal and Hepatic Laboratory Outcomes After Switching to Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate in Treatment-Experienced People with HIV: Real-World Evidence from the SHINe-SHIC Cohort"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5987-3576","authenticated-orcid":false,"given":"Manuela","family":"Ceccarelli","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medicine and Surgery, \u201cKore\u201d University of Enna, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8273-5382","authenticated-orcid":false,"given":"Emmanuele","family":"Venanzi Rullo","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5650-6911","authenticated-orcid":false,"given":"Andrea","family":"Marino","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-5400","authenticated-orcid":false,"given":"Andrea","family":"De Vito","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Azienda Ospedaliera Universitaria di Sassari, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-6676","authenticated-orcid":false,"given":"Cristina","family":"Micali","sequence":"additional","affiliation":[{"name":"Emory National Primate Research Center, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Serena","family":"Spampinato","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Ylenia","family":"Russotto","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0057-3487","authenticated-orcid":false,"given":"Antonio","family":"Albanese","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Azienda Ospedaliera \u201cPapardo\u201d, 98158 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Maria Chiara","family":"Frasca","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Azienda Ospedaliera Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, 95121 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Sonia Agata","family":"Sofia","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Azienda Ospedaliera per l\u2019Emergenza \u201cCannizzaro\u201d, 95126 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9640-8742","authenticated-orcid":false,"given":"Giovanni Francesco","family":"Pellican\u00f2","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"supervision","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6919-1955","authenticated-orcid":false,"given":"Benedetto Maurizio","family":"Celesia","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Paolo","family":"Maggi","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medicine and Surgery, \u201cKore\u201d University of Enna, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"supervision","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6099-2273","authenticated-orcid":false,"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Azienda Ospedaliera Universitaria di Sassari, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"supervision","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8113-8452","authenticated-orcid":false,"given":"Giuseppe","family":"Nunnari","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2026, May 10). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new."},{"key":"ref_2","unstructured":"European AIDS Clinical Society (2026, May 10). EACS Guidelines Version 13.0. Available online: https:\/\/eacs.sanfordguide.com\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e207954","DOI":"10.1001\/jamanetworkopen.2020.7954","article-title":"Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults with and Without HIV Infection, 2000\u20132016","volume":"3","author":"Marcus","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/cid\/ciad545","article-title":"Weight Gain After Antiretroviral Therapy Initiation and Subsequent Risk of Metabolic and Cardiovascular Disease","volume":"78","author":"Bares","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11904-016-0321-0","article-title":"Lipid Abnormalities and Inflammation in HIV Inflection","volume":"13","author":"Funderburg","year":"2016","journal-title":"Curr. HIV AIDS Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","article-title":"Risk Factors for Weight Gain Following Switch to Integrase Inhibitor\u2013Based Antiretroviral Therapy","volume":"71","author":"Lake","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"ofaf639","DOI":"10.1093\/ofid\/ofaf639","article-title":"Factors Associated With Weight Change After Continuing or Switching to a Doravirine-Based Regimen","volume":"12","author":"Orkin","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e02016","DOI":"10.1128\/AAC.02016-18","article-title":"Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions","volume":"63","author":"Khalilieh","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","unstructured":"USA Food and Drug Administration (2026, May 10). PIFELTRO\u00ae (Doravirine) Tablets, for Oral Use, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=210806."},{"key":"ref_12","unstructured":"European Medicine Agency (2026, May 10). Pifeltro: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pifeltro."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","article-title":"Switching to Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate (DOR\/3TC\/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial","volume":"81","author":"Johnson","year":"2019","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/QAI.0000000000002642","article-title":"Brief Report: Switching to DOR\/3TC\/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial","volume":"87","author":"Kumar","year":"2021","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","article-title":"Doravirine versus Ritonavir-Boosted Darunavir in Antiretroviral-Naive Adults with HIV-1 (DRIVE-FORWARD): 96-Week Results of a Randomised, Double-Blind, Non-Inferiority, Phase 3 Trial","volume":"7","author":"Molina","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1097\/QAD.0000000000002350","article-title":"Reversible Effect on Lipids by Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide and Back","volume":"33","author":"Milinkovic","year":"2019","journal-title":"Aids"},{"key":"ref_17","first-page":"1006","article-title":"Which Form of Tenofovir Should Be Used Worldwide: Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide?","volume":"79","author":"Hill","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"ofaf808","DOI":"10.1093\/ofid\/ofaf808","article-title":"Switch to Fixed Dose of Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate Versus Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate in Virologically Suppressed Adults on Efavirenz-Based Regimens: 48-Week Results of a Real-World, Prospective, Observational Cohort Study","volume":"13","author":"Li","year":"2026","journal-title":"Open Forum Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3018(23)00258-8","article-title":"Safety and Efficacy of Doravirine as First-Line Therapy in Adults with HIV-1: Week 192 Results from the Open-Label Extensions of the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Trials","volume":"11","author":"Orkin","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2564286","DOI":"10.1080\/07853890.2025.2564286","article-title":"The Efficacy and Safety of Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate in Treatment-Na\u00efve and Treatment-Experienced Patients with HIV","volume":"57","author":"Yang","year":"2025","journal-title":"Ann. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.18683\/germs.2025.1469","article-title":"Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate (DOR\/3TC\/ TDF) Treatment in People Living with HIV: A Single-Center Real-World Experience from Belgrade, Serbia","volume":"15","author":"Markovic","year":"2025","journal-title":"Germs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/QAI.0000000000002730","article-title":"Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV","volume":"88","author":"Ciccullo","year":"2021","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/13596535211056556","article-title":"Evaluation of Doravirine-Based Regimen Population Target in a Large Italian Clinical Center","volume":"26","author":"Farinacci","year":"2021","journal-title":"Antivir. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e29855","DOI":"10.1097\/MD.0000000000029855","article-title":"Real-Life Use of Doravirine in Treatment-Experienced People Living with HIV: A Multicenter Italian Study","volume":"101","author":"Mazzitelli","year":"2022","journal-title":"Medicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1177\/09564624231195084","article-title":"Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate in Virologically Suppressed People Living with HIV: A Real-Life Experience","volume":"34","author":"Calza","year":"2023","journal-title":"Int. J. STD AIDS"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/QAI.0000000000003248","article-title":"Doravirine Plus Integrase Strand Transfer Inhibitors as a 2-Drug Treatment\u2013Switch Strategy in People Living with HIV: The Real-Life DORINI Multicentric Cohort Study","volume":"94","author":"Poliseno","year":"2023","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Maggi, P., Ricci, E.D., Martinelli, C.V., de Socio, G.V., Squillace, N., Molteni, C., Masiello, A., Orofino, G., Menzaghi, B., and Bellagamba, R. (2023). Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting. Viruses, 15.","DOI":"10.3390\/v15071612"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Maggi, P., Ricci, E.D., Cicalini, S., Pellican\u00f2, G.F., Celesia, B.M., Vichi, F., Cascio, A., Sarchi, E., Orofino, G., and Squillace, N. (2023). Lipids and Transaminase Elevations in ARV-Experienced PLWH Switching to a Doravirine-Based Regimen from Rilpivirine or Other Regimens. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08191-2"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Li, A., Liu, L., Zhang, H., Wang, X., Li, Z., Liu, A., Dai, L., Zhang, J., Gao, Y., and Ye, J. (2025). Efficacy and Safety of Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate in HIV Treatment: A Real-World Single-Center Study in China. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1575411"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/hiv.70061","article-title":"Effectiveness of Switching to Doravirine-based Antiretroviral Therapy: A Real-world Study in Germany","volume":"26","author":"Wyen","year":"2025","journal-title":"HIV Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/QAD.0000000000004151","article-title":"Use of Doravirine-Based Regimens in Clinical Practice in Europe","volume":"39","author":"Rami","year":"2025","journal-title":"AIDS"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus Ritonavir-Boosted Darunavir in Antiretroviral-Naive Adults with HIV-1 (DRIVE-FORWARD): 48-Week Results of a Randomised, Double-Blind, Phase 3, Non-Inferiority Trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/ciaa822","article-title":"Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz\/Emtricitabine\/TDF in Treatment-Naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-Blind, Phase 3 DRIVE-AHEAD Noninferiority Trial","volume":"73","author":"Orkin","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV: A Cohort Study","volume":"174","author":"Surial","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/QAD.0000000000003245","article-title":"Switching from Tenofovir Alafenamide to Tenofovir Disoproxil Fumarate Improves Lipid Profile and Protects from Weight Gain","volume":"36","author":"Kauppinen","year":"2022","journal-title":"AIDS"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cicalini, S., Lanini, S., Gagliardini, R., Bellagamba, R., Vergori, A., Mastrorosa, I., Mazzotta, V., Esvan, R., Plazzi, M.M., and Ottou, S. (2024). Effectiveness and Tolerability of DOR\/3TC\/TDF in Experienced People with HIV Switching from RPV\/FTC\/TDF: A Retrospective, Single Center Cohort Study. Pharmaceuticals, 17.","DOI":"10.3390\/ph17121706"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/hiv.13711","article-title":"DORA: 48-week Weight and Metabolic Changes in Black Women with HIV, in a Phase IIIb Switch Study from Dolutegravir- or Efavirenz- to Doravirine-based First-line Antiretroviral Therapy","volume":"26","author":"Woods","year":"2025","journal-title":"HIV Med."}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7449\/18\/5\/105\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:12:38Z","timestamp":1789636358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/18\/5\/105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["idr18050105"],"URL":"https:\/\/doi.org\/10.3390\/idr18050105","relation":{},"ISSN":["2036-7449"],"issn-type":[{"value":"2036-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}